Home › Trial NCT02063958
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
- Trial IDNCT02063958
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorEsanex Inc.
- Enrollment19
- Start date2014-02
- ConditionsCancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.